Sung Joon Kim

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations

Medicine, Oncology, Pharmacology +15

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Cory M. Johannessen, Jesse S. Boehm, So Young Kim et al. · Nature · 2010 · 1.4K citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +14

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama et al. · Cancer Discovery · 2014 · 842 citations · Full text

Medicine, Oncology, Pharmacology +15

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 412 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

Anna Galkin, Jonathan S. Melnick, Sung Joon Kim et al. · Proceedings of the National Academy of Sciences · 2006 · 377 citations · Full text

Life Sciences, Oncology, Pharmacology +17